Metabolic syndrome after menopause and the role of hormones

Maturitas

Volumn 60, Issue 1, 2008, Pages 10-18

  Lobo, Rogerio A ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

Coagulation; Estrogen; Inflammation; Insulin; Lipids; Metabolic syndrome; Obesity; Oral; Transdermal

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; ESTROGEN; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; TRIACYLGLYCEROL;

ABDOMINAL FAT; BLOOD CLOTTING; BLOOD PRESSURE; BODY MASS; CLINICAL TRIAL; HORMONAL THERAPY; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; OBESITY; POSTMENOPAUSE; PREVALENCE; REVIEW; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MIDDLE AGED; POSTMENOPAUSE; THROMBOSIS; WEIGHT GAIN;

EID: 45649083873     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2008.02.008     Document Type: Review

References (35)

1. WHO European Ministerial Conference on Counteracting Obesity. World Health Organization (2007)
2. Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive Summary of the Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 2001;285: 2486-97.
3. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total cardiovascular disease mortality in middle-aged men. JAMA 288 21 (2002) 2709-2716
4. Ford E.S., Giles W.H., and dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 3 (2002) 356-359
5. Park Y.W., Zhu S., Palaniappa L., et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163 4 (2003) 427-436
6. Sowers M.F., Zheng, Tomey K., et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab 92 3 (2007) 895-901
7. Chu M.C., Cosper P., Orio F., et al. Insulin resistance in postmenopausal women with metabolic syndrome and the measurements of adiponectin, leptin, resistin, and ghrelin. Am J OB/GYN 194 (2006) 100-104
8. Norata G.D., Raselli S., Grigore L., et al. Leptin: adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke (2007) (epub ahead of print)
9. Behre C.J. Adiponectin, obesity and atherosclerosis. Scand J Clin Lab Invest 67 5 (2007) 449-458
10. Salpeter S.R., Walsh J.M.E., Ormiston T.M., et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes, Obesity Metabol 8 (2006) 538-554
11. O'sullivan A.J., Crampton L.I., Freund J., et al. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest 102 (1998) 1035-1040
12. Ho K.K., O'Sullivan A.J., Wolthers T., et al. Metabolic effects of oestrogens: impact of the route of administration. Ann Endocrinol (Paris) 64 (2003) 170-177
13. dos Reis C.M., de Melo N.R., Meirelles E.S., et al. Body composition, visceral fat distribution and fat oxidation in postmenopausal women using oral or transdermal oestrogen. Maturitas 46 (2003) 59-68
14. Di Carlo C., Tommaselli G.A., Sammartino A., et al. Serum leptin levels and body composition in postmenopausal women: effects of hormone therapy. Menopause 11 (2004) 466-473
15. Chu M.C., Cosper P., Nakhuda G., et al. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. Fertil Steril 86 6 (2006) 1669-1675
16. Lindheim S.R., Presser S.C., Ditkoff E.C., et al. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 60 (1993) 664-667
17. Lindheim S.R., Duffy D.M., Kojima T., et al. The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women. Fertil Steril 62 (1994) 1176-1180
18. Cucinelli F., Paparella P., Soranna L., et al. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion. Eur J Endocrinol 140 (1999) 215-223
19. Konayn A.M., Herrington D., Vittinghoff E., et al. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 138 (2003) 1-9
20. Margolis K.L., Bonds D.E., Rodabough R.I., et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the women's health initiative hormone trial. Diabetologia 47 (2004) 1175-1187
21. Ferrara A., Karter A.J., Ackerson L.M., et al. Hormone replacement therapy is associated with better glycemic control in women: the Northern California Kaiser Permanente Diabetes Registry. Diabetes Care 24 7 (2001) 1144-1150
22. Friday K.E., Dong C., and Fontenot R.U. Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 86 1 (2001) 48-52
23. Chu M, Cushman M, Solomon R, Lobo RA. Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation. Presented at Society of Gynecological Investigation 2006.
24. Sumino H., Ichikawa S., Kasama S., et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 189 (2006) 436-442
25. Mueck A.O., Genazzani A.R., Samsioe G., et al. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. Menopause 14 6 (2007) 1-7
26. Lewandowski K.C., Komorowski J., Mikhalidis D.P., et al. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J Clin Endocrinol Metab 91 8 (2006) 3123-3130
27. Sumino H., Ichikawa S., Kasama S., et al. Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. Hypertens Res 28 7 (2005) 579-584
28. Lacut K., Oger E., LeGel G., et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost 90 1 (2003) 124-131
29. The Writing Group for, PEPI. JAMA 273 (1994) 199-208
30. Koh K.K., Yoon R.-K., Merz C.N., et al. The effects of hormone therapy on inflammatory, hemostatic and fibrinolytic markers in postmenopausal women. In: Lobo R.A. (Ed). Treatment of the postmenopausal woman, basic and clinical aspects. Third edition (2007), Elsevier 471-480
31. Scarabin P.Y., Oger E., and Plu-Bueau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362 (2003) 428-432
32. Canonico M., Oger E., Plu-Bureau G., et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Circulation 115 (2007) 840-845
33. Oger E., Martine A.-G., Lacut K., et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women. Arteriosc, Thromb Vasc Biol 23 (2003) 1671-1676
34. Rossouw J.E., Prentice R.L., Manson J.E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297 13 (2007) 1465-1477
35. Zanger D., Yang B.K., Ardans J., et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 36 6 (2000) 1797-1802